REGN Q3 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.8B+0.9% YoY

Gross Profit

$3.2B86.1% margin

Operating Income

$1.0B27.3% margin

Net Income

$1.5B38.9% margin

EPS (Diluted)

$13.62

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$1.6B

Free Cash Flow

$1.4B

Stock-Based Comp.

$237M

Balance Sheet

Total Assets

$40.2B

Total Liabilities

$9.2B

Stockholders' Equity

$31.0B

Cash & Equivalents

$2.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.7B	+0.9%
Gross Profit	$3.2B	$3.2B	+0.1%
Operating Income	$1.0B	$1.2B	-12.9%
Net Income	$1.5B	$1.3B	+8.9%

Revenue Segments

Collaboration Revenue

$2.0B52%

Product

$1.6B42%

Product and Service, Other

$198M5%

Geographic Segments

UNITED STATES

$1.1B88%

Rest Of World

$146M12%